WARNING: “Buffett Indicator” flashing for first time in 50 years

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW

Bertil Lindmark Biography and Net Worth

Insider of Galecto

Bertil Lindmark has had an extensive and successful career in the pharmaceutical industry, building up broad clinical development and regulatory experience globally, and significant expertise in research and development in both large and small pharmaceutical organizations. As Global VP Clinical Development for the Respiratory and Inflammation franchises at AstraZeneca, Bertil led development of Symbicort, one of the worlds’ leading respiratory brands, and many other respiratory and gastro-intestinal products. From 2010, he headed Global R&D at Almirall, involving 500 staff and the successful development and approval of several new drugs in the respiratory, gastro-intestinal, neuroscience and dermatological fields. In 2015 he joined ASLAN Pharmaceuticals in Singapore with a focus on cancer and atopic skin and lung diseases. Bertil holds an MD from Lund University, Sweden with specialties in internal medicine and gastroenterology, and obtained his PhD in molecular epidemiology from Lund University. In 2019, he was appointed visiting Professor Innovation and Entrepreneurship at the Institute of Medicine at Gothenburg University, Sweden.

What is Bertil Lindmark's net worth?: The estimated net worth of Bertil Lindmark is at least $376.00 as of June 28th, 2021. Lindmark owns 80 shares of Galecto stock worth more than $376 as of December 22nd. This net worth estimate does not reflect any other assets that Lindmark may own. Learn More about Bertil Lindmark's net worth.
How do I contact Bertil Lindmark?: The corporate mailing address for Lindmark and other Galecto executives is GALECTO BIOTECH AB OLE MAALOES VEJ3, COPENHAGEN G7, DK-2200. Galecto can also be reached via phone at 45-7070-5210. Learn More on Bertil Lindmark's contact information.
Has Bertil Lindmark been buying or selling shares of Galecto?: Bertil Lindmark has not been actively trading shares of Galecto during the last ninety days. Most recently, on Tuesday, March 22nd, Bertil Lindmark bought 584 shares of Galecto stock. The stock was acquired at an average cost of $54.00 per share, with a total value of $31,536.00. Learn More on Bertil Lindmark's trading history.
Who are Galecto's active insiders?: Galecto's insider roster includes Jonathan Freve (CFO), Bertil Lindmark (Insider), Hans Schambye (CEO), and Garrett Winslow (General Counsel). Learn More on Galecto's active insiders.

Bertil Lindmark Insider Trading History at Galecto

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/22/2022	Buy	584	$54.00	$31,536.00
6/28/2021	Buy	80	$131.50	$10,520.00	80

Bertil Lindmark Buying and Selling Activity at Galecto

Galecto Company Overview

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Today's Range

Now: $4.70

$4.66

$4.86

50 Day Range

MA: $6.22

$4.66

$7.46

2 Week Range

Now: $4.70

$4.40

$23.50

Volume

16,841 shs

Average Volume

16,891 shs

Market Capitalization

$6.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.15